Clinical Report: Enoxaparin Dosing Guided by Anti-Xa Levels in Postoperative Spine Trauma Patients
Overview
This study evaluates the feasibility of anti-Xa-guided enoxaparin dosing in postoperative spine trauma patients, focusing on target attainment and safety outcomes.
Background
Patients undergoing surgery for traumatic spine injuries are at a heightened risk for venous thromboembolism (VTE), which can lead to significant morbidity and mortality. Standard prophylactic regimens may not adequately address this risk, necessitating individualized dosing strategies. Anti-Xa monitoring may optimize enoxaparin dosing.
Data Highlights
Outcome
Anti-Xa Cohort
Fixed Dose Cohort
Symptomatic VTE
1.1%
1.6%
Postoperative epidural hematomas
0
0
Required dose escalation
28%
N/A
Length of stay
No difference
No difference
Key Findings
Symptomatic VTE rates were low and similar between the anti-Xa and fixed dose cohorts (1.1% vs. 1.6%).
No postoperative epidural hematomas were reported in either group.
28% of patients in the anti-Xa cohort required dose escalation.
Bleeding requiring transfusion did not differ significantly between groups.
Length of hospital stay was comparable between the two cohorts.
Clinical Implications
The study evaluates anti-Xa-guided dosing of enoxaparin in postoperative spine trauma patients.
Conclusion
Further prospective studies are warranted to confirm these findings.
by Dallas L. Sheinberg, David Travis Johnston, Brendan T. O'Reilly, Gabriel Galan Castro, Jawad R. Khazaal, Joseph S. Withrow, Duncan J. Trimble, Ankush Chandra, Anthony J. Lim, Derek S. Sheinberg, Jennifer Zaragoza, Wen Li, John R. Williams
